Home / Stocks / Health X Platform Limited
HEALTHX

Health X Platform Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹288.65

Change

-2.0 (-0.69%)

Open

₹287.75

Prev. Close

₹290.65

Day High

₹296.4

Day Low

₹285.2

Volume Analysis

Traded

9,343

Delivered

8,320

Delivery %

89.05%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •Low return on equity (0.29%)
  • •Below-average fundamentals quality score (49/100)
  • •Low operating margin (-4.5%)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹306.16 ₹301.28 ₹294.96 ₹290.08 ₹283.76 ₹278.88 ₹272.56
Fibonacci ₹301.28 ₹297.0 ₹294.36 ₹290.08 ₹285.8 ₹283.16 ₹278.88
Camarilla ₹291.73 ₹290.7 ₹289.68 ₹290.08 ₹287.62 ₹286.6 ₹285.57

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-2.81%

1 Month

-3.8%

3 Months

-6.11%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹40.91

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

-3.64%

Net margin -1.77% × asset turnover 1.41x × equity multiplier 1.46x

Company Overview

Sector

Healthcare

Market Cap

₹908 Cr

P/E (TTM)

510.0

ROE

0.29%

Book Value

₹201.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.

TopFund Analysis

Health X Platform Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (100/100), while Business Quality (20/100) is the weakest area to weigh before deciding. Notably: Low return on equity (0.29%); below-average fundamentals quality score (49/100). FII holding has been rising.

TopFund Score — Fundamentals Quality

49/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

66

Valuation

25

Cash Flow

39

Corporate Governance

56

Momentum

28

Institutional Ownership

53

Business Quality

20

Risk & Volatility

53

Liquidity

50

From Screener.in

  • +Company is almost debt free.
  • +Company is expected to give good quarter
  • +Company's median sales growth is 36.1% of last 10 years
  • +Company's working capital requirements have reduced from 40.4 days to 16.0 days
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of 2.06% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Publication regarding Notice of 37th Annual General Meeting and e-voting information.

37th AGM scheduled for 28 September 2026; annual report link shared with non-registered shareholders.

Company filed FY2025-26 BRSR and disclosed Rs 8 lakh penalty under Companies Act.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 336 358 375 307 270 274 281 286 298 301 346 374 447
Expenses + 327 355 371 317 273 278 305 311 292 324 356 399 455
Operating Profit 9 3 3 -11 -2 -5 -24 -25 6 -23 -10 -25 -8
OPM % 2.76% 0.94% 0.92% -3.47% -0.89% -1.73% -8.43% -8.82% 2.03% -7.5% -3.0% -6.74% -1.88%
Other Income + 12 10 20 18 29 -167 -14 22 25 5 14 13 13
Interest 0 0 0 0 0 0 0 0 0 0 0 0 1
Depreciation 2 2 2 3 2 1 1 1 1 1 2 2 2
Profit before tax 19 11 21 5 25 -174 -39 -5 30 -19 1 -15 2
Tax % -28.85% -23.03% 3.86% -583.03% -102.8% -13.17% 1.99% -478.45% 11.9% -17.17% 59.78% -12.48% -0.51%
Net Profit + 0 -12 -3 22 41 -155 -38 18 27 -15 0 -13 2
EPS in Rs 0 -3 0 5 10 -34 -8 4 8 -4 0 -4 1
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 52 89 135 162 222 388 551 1,798 1,060 1,432 1,159 1,319 1,468
Expenses + 62 116 155 175 255 440 561 684 1,168 1,456 1,177 1,371 1,534
Operating Profit -10 -28 -20 -13 -33 -52 -10 1,114 -107 -24 -19 -52 -67
OPM % -19.0% -31.0% -15.0% -8.0% -15.0% -13.0% -1.9% 62.0% -10.0% -1.7% -1.6% -4.0% -4.5%
Other Income + 2 0 2 7 0 1 1 3 -5 4 -179 57 45
Interest 1 2 3 1 3 1 3 3 2 1 0 1 1
Depreciation 6 7 7 6 6 5 4 4 8 9 6 7 7
Profit before tax -15 -37 -28 -12 -42 -58 -16 1,109 -122 -30 -204 -2 -31
Tax % 0.0% -1.0% 2.0% 19.0% 3.0% -9.0% 4.0% 22.0% -19.0% -119.0% -34.0% -39.0% —
Net Profit + -15 -37 -29 -15 -43 -52 -17 865 -99 6 -134 -1 -26
EPS in Rs -5 -12 -9 -4 -12 -12 -3 197 -23 3 -29 0 -6
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 223 186 163 144 111 178 168 795 722 731 638 609
Borrowings + 5 19 21 12 2 8 12 2 9 4 1 26
Other Liabilities + 22 20 35 48 86 98 80 449 441 383 300 269
Total Liabilities 281 256 251 235 230 316 293 1,278 1,204 1,149 970 936
Fixed Assets + 137 126 125 117 116 114 110 93 107 110 102 117
CWIP 3 0 0 1 1 0 0 0 1 0 10 1
Investments 22 10 17 46 36 56 43 666 513 676 575 519
Other Assets + 119 120 110 71 77 146 139 518 583 363 283 299
Total Assets 281 256 251 235 230 316 293 1,278 1,204 1,149 970 936
Equity Capital 32 32 32 32 32 32 32 32 32 32 32 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -12 -12 -2 -49 -30 -69 -31 -207 -112 36 -17 -74
Cash from Investing Activity + 7 -1 4 15 -2 -22 21 220 133 -34 -1 171
Cash from Financing Activity + 4 13 5 33 26 103 4 -11 -2 -2 0 -80
Net Cash Flow -1 0 7 -2 -6 11 -5 1 19 0 -19 18
CFO/OP 106 43 17 377 89 133 288 -8 104 -172 68 133
Free Cash Flow -28 -18 0 -55 -33 -71 -31 -212 -128 22 -27 -89

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 73.92% → 74.07%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 25.6% 24.73% 24.57% 24.12% 23.11% 22.5% 22.21% 21.79% 21.65% 20.99% 20.38% 21.02%
Promoters 73.92% 73.92% 73.92% 73.92% 73.92% 73.93% 74.11% 74.24% 74.24% 74.69% 74.84% 74.07%
FII 0.32% 0.49% 0.56% 0.61% 0.99% 1.71% 1.6% 1.88% 2.04% 2.25% 2.17% 2.29%
DII 0.17% 0.86% 0.96% 1.35% 1.98% 1.85% 2.06% 2.09% 2.07% 2.07% 2.6% 2.6%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Health X Platform Limited (this stock) 908 510.0 1.42 0.29%
Shree Ganesh Remedies Ltd 946 61.2 5.8 10.8%
Bafna Pharmaceuticals Ltd 842 — 1.65 -6.18%
Gaudium Ivf N Women H L 837 36.2 5.55 24.7%
Kilitch Drugs India Ltd 786 26.2 2.81 10.6%
Wanbury Limited 784 18.2 12.38 76.5%
Zim Laboratories Limited 743 201.0 2.49 1.59%

Which Mutual Funds Hold Health X Platform Limited?

Frequently Asked Questions about Health X Platform Limited

Community Sentiment

What are other investors saying about Health X Platform Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.